# An Introduction to Quantori's Registry Science and Quantori's Practice



### Who is Quantori?

### Combination of Informatics, Registry Science Expertise, Analytics, Combined with Best-in-Class Engineering







Experienced software engineers, data scientists, and applied mathematicians with life science domain expertise



Life science platforms, applications, and tools/ industry awards

Proven expertise and track record of successful application construction, implementation and execution for not-forprofit and Life Sciences organizations



### Quantori: a snapshot



We combine our deep scientific knowledge and pharma digital platform know-how with data science expertise and agile software engineering to help our clients accelerate the development of novel treatments that improve patient lives and advance human health.

Our 650+ member team has experience in the Life Sciences industry domain is complimented with a strong understanding of the principles of regulatory approaches and management of data globally in the US and Europe, as well as the technologies involved.



#### **Major Concentrations & Specialties**

R&D and Early	Scientific Informatics		
Solutions Innovation IT	and Data Sciences		
User-Centric Design,	Data Insight &		
UX & UI	Advanced Analytics		
Product Management &	HPC & Cloud		
Digital Platform	Infrastructure		
Engineering	Enablement		

## What is Registry Science?

### Definition

The procedures, data science and overall capability needed to generate, maintain, and analyze highly specialized, highly curated, multimodal longitudinal data to better define the journey of the study subjects to track long-term outcomes for both clinical and regulatory needs.

Registry science includes not only technology but the following:

- Data and Regulatory Governance
- Security and Privacy
- Technical build and platform
- Long-term data storage and analytics strategies
- Engagement Strategies to maintain longitudinal interactions with participants
- Returning value to participants (when appropriate)
- Returning insights & value to sponsors
- Informing data-driven clinical care decision making
- Safety monitoring (for clinical registries)



# Organizations that find value in creating registries (examples)

Pharmaceutical	Basic Research		
Companies	Organizations		
Rare (orphan) Disease	Data Insight & Advanced		
Research Foundations	Analytics firms		
Patient Advocacy Organizations	Medical Device Manufacturers for long- term safety/efficacy		
Healthcare Provider Orgs	Gov't Agencies that need		
that need to benchmark	to track epidemiology of		
practices	specific diseases		

Any healthcare, business, or government organization that needs to track longitudinal data from multiple sources can benefit from the highly curated nature of data generated by a registry

## **Typical Use Cases for Registries (examples)**





Collecting well curated, longitudinal data remains a common thread for registry use cases

# Why a Registry vs EHR/EMR? EHR

- Broadly focused on episodic patient care
- Optimized for patient care and billing
- Generally not geared as a research environment
- Little effort to deal with missing data
- Data types used in clinical care research data types may not exist
- Episodic care is supported
- Collection on a specific problem not assured
- If patient leaves network or healthcare systems, due to disconnected nature of healthcare, data from other providers may or may not be part of the record
- Production systems across the US have limited interoperability roll-ups are exceptionally difficult

### QUANTORI

### Registry

- Highly focused on a specific condition, problem, or area of research
- Longitudinal data collection is its raison d'etre
- Primarily used for tracking longitudinal trends on very focused questions
- Multimodal data types (research data) often needed and supported (eg: genomics, proteomics or other "omics")
- Can be focused as research or commercial venture (or a blend)
- Can be self-sustaining fund itself by monetizing data assets
- Highly curated for completeness

Registries provide focused, long-term data capabilities that are not generally possible with EHRs

### **Contrasting Two Registry Approaches (as examples)**

### **Research-centric**

- Usually institution-centric
- Main end-user: researchers, clinicians
- Data usually not be used for clinical purposes UNLESS labs or assays run in CLIA mode
- Highly agile, ability to use data nearly immediately
- Always done with oversight (IRBs)
- Often do not share data with patients (less complexity)
- Usually grant funded does not monetize data for sustainability
- Patient recontacting not usually a focus

### **Patient-Centric**

- Main focus is on the patient Patient gets data back from registry
- Can bypass academic organizations
- Can be an "all-comers" strategy (anyone in the country)
- Provides focused data/information/knowledge back to the patient in addition to other stakeholders
- Can grow beyond the focus of one or a few institutions.
- Long-term patient engagement critical for success
- Consent for re-contacting possible
- Can monetize data for sustainability

#### There is no "right answer" - the choice of "kind of registry" is dependent on the use case



### **Our Registry Science Expertise at a Glance: Data and Analytics Excellence**



**Overview:** With over two decades serving the Pharmaceutical & Life sciences industry, Quantori services support end-to-end to create best-in-class registries.



Quantori focuses on the creation of multi-modal, longitudinal data sets for both research and clinical use.

### We Build Workable, Reliable Methods & Means to Create Focused Data For Researchers, Clinicians and Patients





Quantori not only constructs best-in-class systems, but the means to analyze the resultant data

quantori.com

### Descriptive Characteristics of Example Registries

	MMRF CureCloud	ASH	Follicular Lymphoma (in process)	Food Allergy	Hackensack COVID	CFF's Port CF
Focus	Individual PatientsE	De-identified Patients	Individual Patients	De-identified patients	De-identified patients	Identified Patients
Longitudinal						
Clinical Data entered by	Abstraction, Ingestion	EHR ingestion, abstraction	TBD	Patient Survey	EHR abstraction	Clinician-entered
Patient Surveys						
Clinical Data (eg: EHR)						
Genomic		-				
Immunologic						
Claims						
PROs						
Direct to Patients						
Direct to Researcher						
Data used for monetization?						



### Data Entry Considerations: How to get data into the system?

- Do the pre-work on a standardized data dictionary and data model
- Consistent Entry
  - Manual Data Entry eg: CRF
  - Automated data entry eg: EHR ingestion
  - Semi-automated ingestion eg: encoded anonymized matched data entry - such as adding genomic sequencing
  - A combination of the above
- Ensure system can handle metadata or add it on
- If considering EHR data, think twice it's harder than it sounds in 2021
- Regardless of the approach, you need to have good data governance principles in place for checking the data integrity on entry



## The MMRF's CureCloud

The MMRF CureCloud is a Direct-to-Patient Registry with the following goals:

- Create the most comprehensive data set for multiple myeloma for patients, clinicians and researchers
- Democratize data from the system by returning data to patients
- Create an analytics platform to generate best-in-class studies of the mixed data from the system to find new cures
- Create a monetary stream to help sustain the system
- Recruit 5000 patients into the system over the next 5 years run the system for a minimum of 10 years



# A sample high-level architecture for a multi-modal registry



#### This system assumes:

- Direct-to-patient Registry (patient "front door" for data donation)
- Data types
  - EHR data
  - Genomic Data (returned to patients)
  - Proteomic
  - PROs
- Data Visualizations for patients, clinicians and researchers
- Use of a tissue bank



Quantori not only constructs best-in-class systems, but the means to analyze the resultant data



### The CureCloud Workflow



### **The CureCloud Registry**





### **Quantori's Registry Science Team**



**Dr. Steven Labkoff** Global Head, Clinical & Research Informatics



**Dr. Yuriy Gankin** Chief Scientific Officer



Richard Golob Chief Executive Officer

30+ year career in life sciences, informatics, medicine, RWE, biomarkers, clinical trial decision support

Chief Data Officer at Multiple Myeloma Research Foundation - stood up largest myeloma registry in the world

Senior leadership roles at AstraZeneca and Pfizer

Training: Postdoc Medical Informatics, Harvard Medical School & MIT Co-founded GGA Software Services Served as GGA Chief Scientific Officer

Served as Chief Life Sciences Officer at EPAM

PhD in Analytical Chemistry from Tufts and EMBA from MIT Sloan School

Co-founded GGA Software Services

Served as GGA CEO

Served as Global Head, EPAM Life Sciences Business Unit

Built EPAM Life Sciences into company's fastest growing division

AB in Biochemical Sciences at Harvard College